Recent innovations in CAR-T therapy for lymphoma leverage engineered T cells with enhanced capabilities to overcome tumor heterogeneity, the immunosuppressive microenvironment, and T cell exhaustion. Next-generation CAR constructs incorporate multi-target recognition, resistance to inhibitory signals, and increased cytotoxic potency. These developments promise more durable responses by counteracting mechanisms that limit current CAR-T effectiveness, offering hope for improved outcomes in aggressive hematologic cancers.